Buchumschlag

Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy

Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A*02...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Neidert, Marian Christoph (VerfasserIn) , Schoor, Oliver (VerfasserIn) , Trautwein, Claudia (VerfasserIn) , Trautwein, Nico (VerfasserIn) , Christ, Lisa (VerfasserIn) , Melms, Arthur (VerfasserIn) , Honegger, Jürgen (VerfasserIn) , Rammensee, Hans-Georg (VerfasserIn) , Herold-Mende, Christel (VerfasserIn) , Dietrich, Pierre-Yves (VerfasserIn) , Stevanović, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2013
In: Journal of neuro-oncology
Year: 2013, Jahrgang: 111, Heft: 3, Pages: 285-294
ISSN:1573-7373
DOI:10.1007/s11060-012-1028-8
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11060-012-1028-8
Volltext
Verfasserangaben:Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich, Stefan Stevanović
Beschreibung
Zusammenfassung:Glioblastoma multiforme is the most frequent and most malignant primary brain tumor with poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutical strategies have great potential, but the reported repertoire of tumor associated antigens is only for HLA-A*02 positive tumors. We describe the first analysis of HLA-peptide presentation patterns in HLA-A*02 negative glioma tissue combined with gene expression profiling of the tumor samples by oligonucleotide microarrays. We identified numerous candidate peptides for immunotherapy. These are peptides derived from proteins with a well-described role in glioma tumor biology and suitable gene expression profiles such as PTPRZ1, EGFR, SEC61G and TNC. Information obtained from complementary analyses of HLA-A*02 negative tumors not only contributes to the discovery of novel shared glioma antigens, but most importantly provides the opportunity to tailor a patient-individual cocktail of tumor-associated peptides for a personalized, targeted immunotherapeutic approach in HLA-A*02 negative patients.
Beschreibung:Published online: 23 December 2012
Gesehen am 08.12.2021
Beschreibung:Online Resource
ISSN:1573-7373
DOI:10.1007/s11060-012-1028-8

Ähnliche Einträge